GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Cyclically Adjusted PB Ratio

PCI Biotech Holding ASA (FRA:4QG) Cyclically Adjusted PB Ratio : 0.49 (As of Jun. 04, 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Cyclically Adjusted PB Ratio?

As of today (2024-06-04), PCI Biotech Holding ASA's current share price is €0.1556. PCI Biotech Holding ASA's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €0.32. PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio for today is 0.49.

The historical rank and industry rank for PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:4QG' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.62
Current: 0.5

During the past years, PCI Biotech Holding ASA's highest Cyclically Adjusted PB Ratio was 0.62. The lowest was 0.00. And the median was 0.00.

FRA:4QG's Cyclically Adjusted PB Ratio is ranked better than
74.09% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs FRA:4QG: 0.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

PCI Biotech Holding ASA's adjusted book value per share data for the three months ended in Jun. 2023 was €0.107. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.32 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


PCI Biotech Holding ASA Cyclically Adjusted PB Ratio Historical Data

The historical data trend for PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Cyclically Adjusted PB Ratio Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.61 5.94 3.18 0.51 -

PCI Biotech Holding ASA Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.51 0.52 0.54 -

Competitive Comparison of PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio falls into.



PCI Biotech Holding ASA Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.1556/0.32
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, PCI Biotech Holding ASA's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.107/130.4000*130.4000
=0.107

Current CPI (Jun. 2023) = 130.4000.

PCI Biotech Holding ASA Quarterly Data

Book Value per Share CPI Adj_Book
201309 0.502 96.400 0.679
201312 0.399 96.600 0.539
201403 0.323 97.300 0.433
201406 0.253 97.500 0.338
201409 0.179 98.500 0.237
201412 0.078 98.600 0.103
201503 0.364 99.200 0.478
201506 0.326 100.100 0.425
201509 0.262 100.600 0.340
201512 0.218 100.900 0.282
201603 0.185 102.500 0.235
201606 0.143 103.800 0.180
201609 0.099 104.200 0.124
201612 0.090 104.400 0.112
201703 0.283 105.000 0.351
201706 0.247 105.800 0.304
201709 0.222 105.900 0.273
201712 0.158 106.100 0.194
201803 0.111 107.300 0.135
201806 0.088 108.500 0.106
201809 0.062 109.500 0.074
201812 0.932 109.800 1.107
201903 0.879 110.400 1.038
201906 0.803 110.600 0.947
201909 0.755 111.100 0.886
201912 0.682 111.300 0.799
202003 0.618 111.200 0.725
202006 0.581 112.100 0.676
202009 0.526 112.900 0.608
202012 0.479 112.900 0.553
202103 0.446 114.600 0.507
202106 0.406 115.300 0.459
202109 0.358 117.500 0.397
202112 0.300 118.900 0.329
202203 0.245 119.800 0.267
202206 0.197 122.600 0.210
202209 0.167 125.600 0.173
202212 0.147 125.900 0.152
202303 0.124 127.600 0.127
202306 0.107 130.400 0.107

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PCI Biotech Holding ASA  (FRA:4QG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PCI Biotech Holding ASA Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA (FRA:4QG) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (FRA:4QG) Headlines

No Headlines